510 results about "Cancer chemotherapy" patented technology

The invention provides novel compositions, methods and uses, for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia and cancer. The invention further relates to genes that are differentially expressed in tissue of cancer patients versus those of normal “healthy” tissue. Differentially expressed genes for the identification of patients which are likely to respond to chemotherapy are also provided. The present invention relates to methods for prognosis the prediction of therapeutic success in cancer therapy. In a preferred embodiment of the invention it relates to methods for prediction of therapeutic success of combinations of signal transduction inhibitors, therapeutic antibodies, radio- and chemotherapy. The methods of the invention are based on determination of expression levels of 48 human genes which are differentially expressed prior to the onset of anti-cancer chemotherapy. The methods and compositions of the invention are most useful in the investigation of advanced colorectal cancer, but are useful in the investigation of other types of cancer and therapies as well.

Vasoconstrictors are administered topically to provide protection against the adverse effects, e.g., alopecia, mucositis or dermatitis, induced by chemotherapy or radiotherapy. Appropriate dosages and formulations of topical vasoconstrictors are provided. Methods for the use of such compositions are also provided.

The product of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide having a plasmin peptide substrate of 2-4 amino acids and mono- or di-peptide linkage, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by plasmin. Also disclosed are methods of making and using the prodrug compounds.

The present invention relates to ketone derivatives represented by the following formula and medical agents containing the ketone derivatives or pharmacologically acceptable salts thereof as an active ingredient, and in particular, relates to a hematopoietic agent; it is shown that the present invention increases blood cells, such as platelets, white blood cells, and red blood cells, and is effective in preventing and treating cytopenia caused by cancer chemotherapy, radiation therapy, and the like.

The use in preparation of a medicament for treating and preventing the side effects of anti-cancer chemotherapy of a polyunsaturated fatty acid with a carbon chain length of 14 to 26 and with 2 to 6 double bonds in the molecule in cis or trans configuration, and a method of such treatment or prevention wherein said fatty acid is used as an active.

The invention provides novel polyamine and amino thiol compounds and pharmaceutical compositions for administration in conjunction with cancer chemotherapy or radiation therapy. The compounds are administered locally to provide protection against the adverse side-effects of chemotherapy or radiation therapy, such as alopecia, mucositis and dermatitis. Pharmaceutical preparations comprising one or more chemoprotective polyamines or amino thiols formulated for topical or local delivery to epithelial or mucosal cells are disclosed. Methods of administering the pharmaceutical preparations are also disclosed.

The invention discloses a nano-carrier particle controllable in drug release, which has a three-layer core-shell structure and comprises outer-layer mesoporous silica, an interlayer silica shell layer and an inner-layer gold nanorod; drug is loaded in the mesoporous silica; raman molecule is coated on the silica shell layer; the raman molecule is marked on the gold nanorod; the drug is connected on the mesoporous silica by a molecule containing a disulfide bond in a manner of a covalent bond, and the disulfide bond is cut off under the action of glutathione in a cell, so as to release the drug molecule. The invention also discloses a preparation method of the nano-carrier particle controllable in drug release. The nano-drug carrier particle and the preparation method can effectively avoid advance leakage of the drug and reduce the toxic and side effects of the drug, and simultaneously, SERS (surface enhanced raman scattering) signals are integrated in the nano-drug carrier particle, so that precise optical tracing on the nano-drug carrier particle is realized, great convenience is brought to the research on administration behavior, and can effectively improve the cancer chemotherapy efficiency.

The invention discloses an oral composition containing Ectoine and hyaluronic acid and application of the oral composition. The oral composition is prepared from, by mass, 0.1-5% of high molecular weight hyaluronic acid or salt thereof, 0.1-5% of low molecular weight hyaluronic acid or salt thereof, 0.01-1% of tea polyphenol, 1-3% of xylitol, 0.1-1% of Ectoine and the balance water, and the totalpercentage is 100%. Accordingly, the Ectoine, different molecular weights of hyaluronic acid or salt thereof, tea polyphenol and xylitol are compounded, the bio-safety is high, the synergetic effect is achieved, the effects of nursing wound surfaces, diminishing inflammation, promoting healing and the like are achieved, and the oral composition is applicable to oral care application such as oral care after cancer chemotherapy and oral ulcer care and can also be applied to the field of medical products, medical equipment and disinfection products.

The present invention relates to Pyridyl-Substituted Porphyrin Compounds, compositions comprising an effective amount of a Pyridyl-Substituted Porphyrin Compound and methods for treating or preventing injury due to exposure to a reactive species, erectile dysfunction due to surgery, lung disease, hyperoxia, neurodegenerative disease, liver disease, myocardial damage during cardioplegia, an inflammatory condition, a reperfusion injury, an ischemic condition, a cardiovascular disease, diabetes, a diabetic complication, cancer, a side effect of cancer chemotherapy, or a radiation-induced injury, or to prolong the half-life of an oxidation-prone compound, comprising administering to a subject in need thereof an effective amount of a Pyridyl-Substituted Porphyrin Compound.

The present invention relates to prognostic methods which are useful in medicine, particularly cancer chemotherapy. The object of the invention to provide a method for assessing TS and/or ERCC1 expression levels in fixed or fixed and paraffin embedded tissues and prognosticate the probable resistance of a patient's tumor to treatment with 5-FU and oxaliplatin-based therapies by examination of the amount of TS and/or ERCC1 mRNA in a patient's tumor cells and comparing it to a predetermined threshold expression level for those genes. More specifically, the invention provides to oligonucleotide primer pairs ERCC1 and TS and methods comprising their use for detecting levels of ERCC1 and TS mRNA, respectively.

The present invention is a method of treating a person who has psoriasis or arthritis or reducing the toxicity of cancer chemotherapy which comprises administering to the patient an anti-psoriasis effective amount of an oxazolidinone, preferably (S)-N-[[3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide.

Disclosed are pharmacophores for developing and screening compounds having G-protein-coupled receptor antagonist activity, including LPA₁, LPA₂, LPA₃ and S1P antagonists. These compositions have therapeutic benefit in the fields of cancer chemotherapy, cardiovascular disease prevention, and fertility protective agents during radiation and chemotherapy.

The present invention relates to prognostic methods which are useful in medicine, particularly cancer chemotherapy. The object of the invention to provide a method for assessing ERCC1 expression levels in fixed or fixed and paraffin embedded tissues and determine a platinum-based chemotherapy by examination of the amount of ERCC1 mRNA in a patient's tumor cells and comparing it to a predetermined threshold expression level. More specifically, the invention provides to oligonucleotide primer pair ERCC1 and methods comprising their use for detecting levels of ERCC1 mRNA.

Disclosed herein are novel pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration. Also included are formulations including both aprepitant and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.

The present invention relates to cyclic ketones represented by the following formulaand to drugs in which an effective component is such a cyclic ketone or a pharmacologically acceptable salt thereof.The cyclic ketones of the present invention encourage the production of blood platelets, leukocytes and erythrocytes, and can be employed in the prevention or treatment of cytopaenia brought about by cancer chemotherapy, radiotherapy or drug therapy, or by immunological abnormality, anaemia and the like.

A prognostic assay and kit and method of use thereof are provided. The kit and assay are used to determine the likelihood of a diseased cell or tissue having a therapeutic response to treatment with a cardiac glycoside in a disease having an etiology associated with excessive cell proliferation. The kit and assay are used to determine the ratio of isoforms of the α subunit of Na, K-ATPase obtained from the diseased cell or tissue. The kit can be used to predict the therapeutic responsiveness of cancer or tumor in a subject to treatment with a cardiac glycoside. The kit and assay can be incorporated in a method of treating a disease or disorder having an etiology associated with excessive cell proliferation with a composition comprising a cardiac glycoside.

Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.

The objective of the invention is to provide a traditional Chinese medicine granule for treating side effects on an alimentary canal after cancer chemotherapy and a preparation method thereof. The invention is characterized in that the granule is prepared from an active component, a binder and pharmaceutically acceptable adjuvant, and the active component is prepared from the traditional Chinese medicines consisting of 600 to 800 g of milkvetch root, 250 to 350 g of dwarf lilyturf tuber, 150 to 250 g of red ginseng, 150 to 250 g of white atractylodes rhizome fried with bran, 150 to 250 g of Poria cocos, 200 to 300 g of licorice, 200 to 300 g of radix scrophulariae, 200 to 300 g of Chinese angelica, 250 to 350 g of dark plum, 250 to 350 g of prepared pinellia tuber, 200 to 300 g of cablin patchouli herb, 200 to 300 g of dried orange peel and 200 to 300 g of curcuma rhizome. The granule is applicable to cancer patients who vomit or retch because of damage of both qi and yin and rising of stomach qi resulting from damage of the spleen and the stomach by anti-radiogenic cancer and chemotherapy drugs, and the granule can mitigate symptoms like no appetite, tiredness, hypodynamia, a red or light red tongue with little fluid and weak pulse.

Methods of application of Schisandrin B in the preparation of anticancer medications, and particularly for the preparation of medications for the treatment of multidrug resistant (MDR) cancer. The compound of Schisandrin B effectively reverses MDR cancer in combination with other anticancer chemotherapeutic agents. Schisandrin B reverses MDR cancer by inhibiting the drug efflux activity of P-glycoprotein, indicating its significance in clinical applications. Although it is of low toxicity, Schisandrin B is cytotoxic to human cancer cells, revealing its application in cancer chemotherapy. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.